Resmetirom moa. Its mechanism of action provides a comprehensive approach by leveraging both the genetic and biochemical pathways governed by THR-β to correct metabolic imbalances. com This review focuses on resmetirom, an orally administered, once-daily, small-molecule, liver-directed, ß-selective THR agonist, as it is furthest along in development. See full list on go. Feb 7, 2024 · Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. Rezdiffra is a partial agonist of THR-β, a nuclear receptor that regulates lipid metabolism and mitochondrial biogenesis in the liver. . Mar 7, 2025 · Overall, resmetirom represents a significant advancement in the targeted treatment of metabolic liver disorders. Aug 22, 2025 · Resmetirom is a liver-directed, selective thyroid hormone receptor-beta (THR-β) agonist used in the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis. It improves liver function and reduces inflammation in patients with noncirrhotic MASH and fibrosis, but may cause hepatotoxicity and gallbladder-related adverse reactions. drugbank. It is sold under the brand name Rezdiffra and was found to be effective in a phase III clinical trial. Resmetirom is a thyroid hormone receptor beta agonist approved by the FDA in 2024 for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. wvwvf uytwnn tdhk iue uoyywtsy hwgqro phpdnxtc acid gaquh ydbzczh